A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic leukemia (CLL). For young, fit patients the standard of care is combination of fludarabine, cyclophosphamide, and rituximab (FCR). Based on the preclinical work demonstrating that bendamustine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Jain, Nitin, Balakrishnan, Kumudha, Ferrajoli, Alessandra, O’Brien, Susan M., Burger, Jan A., Kadia, Tapan M., Cortes, Jorge E., Ayres, Mary L., Tambaro, Francesco Paolo, Keating, Michael J., Gandhi, Varsha, Wierda, William G.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400650/
https://ncbi.nlm.nih.gov/pubmed/27655665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados